hrp0089p3-p204 | GH & IGFs P3 | ESPE2018

Children Born Small for Gestational Age Treated with Growth Hormone: Evolutionary Aspects

Vazquez Veronica Maria Padin , Costa David Albino Gomez , Garcia Aida Del Campo , Cordo Lourdes Rey , Martin Jose Luis Chamorro , Lorenzo Jose Ramon Fernandez

Introduction: Short stature is defined as stature less than −2 standars deviations (SD) for a person’s age and sex of the reference population. Short for gestational age children (SGA) represent 20% of all children with short stature. 10% of these can not catch-up and remains their height below −2 SD. Growth hormone (GH) treatment is a recognized therapy for SGA children authorized in Europe at 4 years old. There are studies that support that younger children ...

hrp0082p3-d2-889 | Perinatal and Neonatal Endocrinology (1) | ESPE2014

Evolution and Epidemiological Assessment of the Influence of Sociological Variables of Children Born SGA in the Last Decade in Basque Country

Diez-Lopez Ignacio , Hoyo-Moracho Marta , Sarasua-Miranda Ainhoa , Lorente-Blazquez Isabel , Rodriguez-Rivera Victor Manuel , Macarulla-Arenaza Maria Teresa , de Segura Lorente Raquel Gomez , Campos Dorleta Perez

Background: Although the theoretical impact of small in weight and/or size at birth (<2 SDS for EG) is 3–5% (3.5% in the Basque Country (source: Local Government) the socio-economic situation in our country has conditioned a change in its l although 50% at 2 years did not do a proper catch up (by excess or defect) with potential impact on future size and metabolic complications, cardiovascular require specific monitoring.Objective: To assess soc...

hrp0097p1-404 | Adrenals and HPA Axis | ESPE2023

Nephrocalcinosis: an emerging issue in children with Congenital Adrenal Hyperplasia

Chiarito Mariangela , Lattanzio Crescenza , D'Ascanio Vito , Capalbo Donatella , Cavarzere Paolo , Grandone Anna , Luongo Caterina , Pepe Giorgia , Wasniewska Malgorzata , Zoller Thomas , Salerno Mariacarolina , Felicia Faienza Maria

Hypercalcemia and nephrocalcinosis (NC) are rare findings associated with congenital adrenal hyperplasia (CAH), whose pathogenetic mechanisms are still unclear. In this study we aimed to investigate the prevalence of NC in a cohort of Italian children affected with classical form of CAH, and to correlate its association with metabolic control of the disease.Subjects and Methods: This is a multicenter one year-perspective study involving ...

hrp0097p1-359 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

An Evaluation of coping strategies in girls diagnosed of central precocious puberty before and after the COVID-19 lockdown, and in their mothers: preliminary study.

E Street Maria , Rollo Dolores , Rossi Maurizio , Sartori Chiara , Petraroli Maddalena , Pilloni Simone , Francavilla Roberta , Lattanzi Claudia , Miglioli Irene , Iughetti Lorenzo , Stagi Stefano

During the COVID-19 pandemic, a significant increase in Central Precocious Puberty(CPP) has been observed worldwide. The reasons for this phenomenon are yet unclear. In order to evaluate if fear, stress and coping strategies used by children and parents when dealing with negative emotional situations and health issues might have acted as triggers for this phenomenon, we administered specific questionnaires to girls who had a diagnosis of CPP before and after the COVID-19 relat...

hrp0097p1-186 | Thyroid | ESPE2023

Comparison of clinical features, therapy, and disease evolution in a population of children and adolescents with Graves' disease and Type 1 Diabetes compared to Graves' disease alone.

Bernardini Luca , Maltoni Giulio , Cristina Vigone Maria , Franceschi Roberto , Cardinale Giuliana , Mameli Chiara , Piscopo Alessia , Roppolo Rosalia , Savastio Silvia , Ortolani Federica , Randazzo Emioli , Giulia Lambertini Anna , Cassio Alessandra

Introduction: About 25% of children and adolescents with Type 1 Diabetes (T1D) have one or more associated autoimmune conditions. Although Graves' disease (GD) rarely occurs, considering the potential severity of manifestations, an early diagnosis and appropriate treatment are essential. The first line treatment is methimazole, whose use is not free from side effects; therefore, it is important to start with the most appropriate dosage.<p class="abste...

hrp0097p1-17 | Bone, Growth Plate and Mineral Metabolism | ESPE2023

Dual-X-ray-Absorptiometry (DXA) bone parameters in children with Achondroplasia

Angelelli Alessia , Fava Daniela , Elsa Maria Allegri Anna , Casalini Emilio , Napoli Flavia , Ridella Francesca , Tedesco Caterina , Maghnie Mohamad , Di Iorgi Natascia

Achondroplasia is the most common skeletal dysplasia caused by a gain of function of the fibroblast growth factor receptor 3(FGFR3) that impairs endochondral ossification, exiting in short stature and altered bone microarchitecture. Although fractures and reduced bone mineralization are not comorbidities frequently reported, specific normative DXA data are lacking. Aim of the study was to assess bone density parameters in an Achondroplasia cohort. Fifty-seven patients (Female-...

hrp0095p1-214 | Adrenals and HPA Axis | ESPE2022

Development and validation of simultaneous quantification of urinary catecholamines and free metanephrines by UHPLC-MS/MS method

Eugenia Rodriguez Maria , Gabriela Ballerini Maria , Ambao Veronica , Vieites Ana , Sanso Gabriela , Rey Rodolfo , Bergada Ignacio , Gabriela Ropelato Maria

Background: Neuroendocrine tumors from adrenal and extra-adrenal chromaffin cells are characterized by overproduction of catecholamines (CA), leading to the increase of urinary O-methylated metabolites (uO-Met) excretion, reliable biomarkers for the initial screening, diagnosis and monitoring of patients with pheochromocytoma and paragangliomas (PPGLs).Objective: To develop and validate a UHPLC-MS/MS method for the simul...

hrp0089p1-p147 | GH &amp; IGFs P1 | ESPE2018

Serum IGFBP-2 Concentration in Neonates with Potential Diagnosis of Growth Hormone Deficiency (GHD)

Gabriela Ballerini Maria , Braslavsky Debora , Keselman Ana , Eugenia Rodriguez Maria , Gotta Gabriela , Gabriela Ropelato Maria , Bergada Ignacio

In a retrospective study (1), we found that a GH<6.5 μg/L, IGF-I-WHO87/518 <30 μg/L and IGFBP-3<0.8 μg/mL confirmed GHD diagnosis with high diagnostic accuracy in neonates with clinical suspicion of GHD. GH and insulin negatively regulate IGFBP-2, and it was proposed to reflect GH status in the diagnostic work-out of GHD in childhood and adults. The accuracy of IGFBP-2 has not been set for neonates.Objective: To prospectively v...

hrp0086p2-p774 | Pituitary and Neuroendocrinology P2 | ESPE2016

Insulin Sensitivity in Girls with Central Precocious Puberty at Diagnosis and at 6 Months of GnRH Analogue Treatment

Arcari Andrea , Freire Analia , Escobar Maria Eugenia , Ballerini Maria Gabriela , Ropelato Maria Gabriela , Bergada Ignacio , Gryngarten Mirta

Background: Puberty is associated with a physiological decline in insulin sensitivity. Overweight and obesity are common among girls with Central Precocious Puberty (CPP). CPP and early menarche have been considered as risk factors for obesity and cardiovascular diseases during adulthood. Besides, concern has been raised by the potential impact of GnRH analogues (GnRH-a) treatment on body weight and metabolic profile.Objective and hypotheses: To evaluate...

hrp0082p2-d3-342 | Diabetes (2) | ESPE2014

Prolonged Treatment with Vitamin D Supplementation and High Dose is Necessary to Treat Vitamin D Deficiency/Insufficiency (VDD/I) in Children and Adolescents with Type 1 Diabetes

Xatzipsalti Maria , Dolianiti Maria , Papadopoulou Konstantina , Kouloufakou Penelope , Mitravela Vasiliki-Ioanna , Dracopoulou Maria , Stamogiannou Lela , Vazeou Andriani

Background: Increased frequency of VDD/I has been found in warmer countries over the last years.Objective and hypotheses: To evaluate the response to vitamin D treatment in VDD/I among children and adolescents with type 1 diabetes.Method: Total 25OHvitamin D levels (VDL) were measured in 76 consecutive children and adolescents with type 1 diabetes (36 males, mean age (S.D.) 13.6 (5.09) years, median disease duration ...